Literature DB >> 22906945

Vaccines against Toxoplasma gondii: status, challenges and future directions.

Qi Liu1, Lachhman Das Singla, Huaiyu Zhou.   

Abstract

Toxoplasma gondii is a ubiquitous protozoan parasite that can infect a wide range of animals including humans. This single known species in the genus Toxoplasma is considered as one of the most successful eukaryotic pathogens which is of major medical and veterinary importance. Effective vaccines may contribute toward preventing and controlling the spread of toxoplasmosis. The present communication addresses the current status of development of vaccines against T. gondii. Further discussion is made on the difficulties along with challenges, such as vaccine construct, mode of vaccine administration and standardization of immunization evaluation. Finally suggestions are made on possible directions for future research on the development of vaccines against T. gondii.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22906945      PMCID: PMC3579912          DOI: 10.4161/hv.21006

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  23 in total

Review 1.  DNA vaccines: capacity to induce auto-immunity and tolerance.

Authors:  D M Klinman; F Takeshita; S Kamstrup; S Takeshita; K Ishii; M Ichino; H Yamada
Journal:  Dev Biol (Basel)       Date:  2000

Review 2.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

Review 3.  Vaccines against Toxoplasma gondii: challenges and opportunities.

Authors:  Erik Jongert; Craig W Roberts; Nicola Gargano; Elisabeth Förster-Waldl; Elisabeth Förster-Wald; Eskild Petersen
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-03       Impact factor: 2.743

Review 4.  Vaccination as a control strategy against the coccidial parasites Eimeria, Toxoplasma and Neospora.

Authors:  E A Innes; A N Vermeulen
Journal:  Parasitology       Date:  2006       Impact factor: 3.234

5.  TLR, NLR Agonists, and Other Immune Modulators as Infectious Disease Vaccine Adjuvants.

Authors:  Sarah C Higgins; Kingston H G Mills
Journal:  Curr Infect Dis Rep       Date:  2010-01       Impact factor: 3.725

Review 6.  Immunological mechanisms of vaccination.

Authors:  Bali Pulendran; Rafi Ahmed
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

Review 7.  DNA vaccines: an historical perspective and view to the future.

Authors:  Margaret A Liu
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 8.  Toxoplasmosis.

Authors:  J G Montoya; O Liesenfeld
Journal:  Lancet       Date:  2004-06-12       Impact factor: 79.321

Review 9.  Toxoplasma gondii proteomics.

Authors:  Louis M Weiss; Andras Fiser; Ruth Hogue Angeletti; Kami Kim
Journal:  Expert Rev Proteomics       Date:  2009-06       Impact factor: 3.940

Review 10.  Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection.

Authors:  E Y Denkers; R T Gazzinelli
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

View more
  31 in total

Review 1.  Nanomedicine advances in toxoplasmosis: diagnostic, treatment, and vaccine applications.

Authors:  João Paulo Assolini; Virginia Márcia Concato; Manoela Daiele Gonçalves; Amanda Cristina Machado Carloto; Ivete Conchon-Costa; Wander Rogério Pavanelli; Francine Nesello Melanda; Idessania Nazareth Costa
Journal:  Parasitol Res       Date:  2017-05-05       Impact factor: 2.289

2.  AMA1-deficient Toxoplasma gondii parasites transiently colonize mice and trigger an innate immune response that leads to long-lasting protective immunity.

Authors:  Vanessa Lagal; Márcia Dinis; Dominique Cannella; Daniel Bargieri; Virginie Gonzalez; Nicole Andenmatten; Markus Meissner; Isabelle Tardieux
Journal:  Infect Immun       Date:  2015-04-06       Impact factor: 3.441

Review 3.  REVIEW OF DNA VACCINE APPROACHES AGAINST THE PARASITE TOXOPLASMA GONDII.

Authors:  Rosalie C Warner; Ryan C Chapman; Brianna N Davis; Paul H Davis
Journal:  J Parasitol       Date:  2021-11-01       Impact factor: 1.276

4.  Delayed IL-12 production by macrophages during Toxoplasma gondii infection is regulated by miR-187.

Authors:  Heng Jiang; Tao Zhai; Yanhui Yu; Xin Li; Pengtao Gong; Xichen Zhang; Guojiang Li; Jianhua Li
Journal:  Parasitol Res       Date:  2020-02-17       Impact factor: 2.289

5.  Toxoplasma gondii: immune response and protective efficacy induced by ROP16/GRA7 multicomponent DNA vaccine with a genetic adjuvant B7-2.

Authors:  Qi Liu; Fuwu Wang; Guan Wang; Qunli Zhao; Juan Min; Shuai Wang; Hua Cong; Ying Li; Shenyi He; Huaiyu Zhou
Journal:  Hum Vaccin Immunother       Date:  2013-10-07       Impact factor: 3.452

6.  Immune Stimulation of RAP domain binding protein (rTgRA15) from Toxoplasma gondii.

Authors:  Min Han Lew; Rahmah Noordin; Mohammed Monsur Alam Khan; Gee Jun Tye
Journal:  Pathog Glob Health       Date:  2018-10-17       Impact factor: 2.894

7.  1,3,4-Thiadiazoles Effectively Inhibit Proliferation of Toxoplasma gondii.

Authors:  Lidia Węglińska; Adrian Bekier; Katarzyna Dzitko; Barbara Pacholczyk-Sienicka; Łukasz Albrecht; Tomasz Plech; Piotr Paneth; Agata Paneth
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

8.  Toxoplasma gondii cathepsin proteases are undeveloped prominent vaccine antigens against toxoplasmosis.

Authors:  Guanghui Zhao; Aihua Zhou; Gang Lv; Min Meng; Min Sun; Yang Bai; Yali Han; Lin Wang; Huaiyu Zhou; Hua Cong; Qunli Zhao; Xing-Quan Zhu; Shenyi He
Journal:  BMC Infect Dis       Date:  2013-05-07       Impact factor: 3.090

Review 9.  Diagnosis of toxoplasmosis and typing of Toxoplasma gondii.

Authors:  Quan Liu; Ze-Dong Wang; Si-Yang Huang; Xing-Quan Zhu
Journal:  Parasit Vectors       Date:  2015-05-28       Impact factor: 3.876

10.  Fatal Toxoplasma gondii infection in the giant panda.

Authors:  Hongyu Ma; Zedong Wang; Chengdong Wang; Caiwu Li; Feng Wei; Quan Liu
Journal:  Parasite       Date:  2015-10-29       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.